Company Presentation
STALICLA SA
| Country: | Switzerland |
| Category: | Clinical Stage Biotech Company |
| Room: | Samarkand |
| Date: | 22.04.2024. |
| Time: | 16:45 – 17:00 |
| Website: | https://stalicla.com |
| Speaker: | Lynn Durham, CEO & Founder |
Company profile
Stalicla, a global biotech, focuses on precision medicine for brain diseases. Founded in 2017, it’s raised $75m+. DEPI, its neuro precision platform, targets Autism Spectrum Disorder with STP1 and STP2 in Phase 2. STP7, licensed from Novartis, is in Phase III trials for substance use disorders with NIH. STALICLA plans a $75m-Series C to advance STP1 & STP2, expand STP7’s indications, and develop a new PhII asset with secured $24m financing.
